Skip navigation

Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives and Strategic Best Practices for Implementation

September 18-19, 2019
  • Philadelphia, PA

Breaking News For Manufacturers: Wednesday, May 8th, 2019 — The HHS formally announced its ruling requiring drug manufacturers to include list prices in television advertisements. This rule will go into effect 60 days after it is published in the Federal Register, which is expected to be Friday, May 10th. Pharma companies will need to comply to this ruling quickly. Impact on patients remains uncertain. Join us in September to discuss the effects of this drug pricing transparency ruling.

In light of recent focus on HHS’s proposal to eliminate rebates, the Senate Finance hearing with Pharma CEOs, and a strong legislative movement towards transparency, there is a heightened focus on drug pricing transparency in the United States. Recent federal and state rulings create lingering questions around legislation and compliance complexities that will impact the market in real-time causing uncertainty.

Join CBI’s 5th Edition Drug Pricing Transparency Congress, to convene with stakeholders to forecast how drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Assess the advancements of legislation made in 2019, collaborate to scenario plan for the future and share best practices for implementation.

Don’t miss this timely update on state transparency laws — register today!

New For 2019!

  • Anticipate New State Legislations to Watch for 2020 —
    A Practical Analysis
  • Examine Trade Secret Protections for Compliance
  • Benchmarking Survey Results Reveal
  • Scenario Planning — Investigations, Litigations and Policy Considerations for State Drug Pricing Transparency Laws
  • TWO preconference workshops:
    • Drug Pricing Transparency Bootcamp —
      Key Considerations and Learnings For Reporting
    • What to Do When You’re Expecting —
      Deep Dive into the Proposed Rule to Eliminate Safe Harbor on Rebates
  • And more!

Back By Popular Demand:

  • State-By-State Analysis Showcase
    • Evaluate New State Legislations —
      Status Report on Washington and Maryland
    • Update on Existing Transparency Laws Including California and Oregon
  • Industry Talk — Set up an Internal Team to Respond to
    Drug Pricing Transparency Laws
  • State Drug Pricing Transparency Level-Set —
    Reporting and Requirements Landscape
  • Federal Spotlight —
    Status Update on Federal Initiatives for Transparency

Download the Conference Preview

5th Edition Drug Pricing Transparency Congress

Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives and Strategic Best Practices for Implementation

Breaking News For Manufacturers: Wednesday, May 8th, 2019 — The HHS formally announced its ruling requiring drug manufacturers to include list prices in television advertisements. This rule will go into effect 60 days after it is published in the Federal Register, which is expected to be Friday, May 10th. Pharma companies will need to comply to this ruling quickly. Impact on patients remains uncertain. Join us in September to discuss the effects of this drug pricing transparency ruling.

In light of recent focus on HHS’s proposal to eliminate rebates, the Senate Finance hearing with Pharma CEOs, and a strong legislative movement towards transparency, there is a heightened focus on drug pricing transparency in the United States. Recent federal and state rulings create lingering questions around legislation and compliance complexities that will impact the market in real-time causing uncertainty.

Join CBI’s 5th Edition Drug Pricing Transparency Congress, to convene with stakeholders to forecast how drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Assess the advancements of legislation made in 2019, collaborate to scenario plan for the future and share best practices for implementation.

Don’t miss this timely update on state transparency laws — register today!

New For 2019!

  • Anticipate New State Legislations to Watch for 2020 —
    A Practical Analysis
  • Examine Trade Secret Protections for Compliance
  • Benchmarking Survey Results Reveal
  • Scenario Planning — Investigations, Litigations and Policy Considerations for State Drug Pricing Transparency Laws
  • TWO preconference workshops:
    • Drug Pricing Transparency Bootcamp —
      Key Considerations and Learnings For Reporting
    • What to Do When You’re Expecting —
      Deep Dive into the Proposed Rule to Eliminate Safe Harbor on Rebates
  • And more!

Back By Popular Demand:

  • State-By-State Analysis Showcase
    • Evaluate New State Legislations —
      Status Report on Washington and Maryland
    • Update on Existing Transparency Laws Including California and Oregon
  • Industry Talk — Set up an Internal Team to Respond to
    Drug Pricing Transparency Laws
  • State Drug Pricing Transparency Level-Set —
    Reporting and Requirements Landscape
  • Federal Spotlight —
    Status Update on Federal Initiatives for Transparency

Download the Conference Preview